Crinetics Pharmaceuticals, Inc.
CRNX
Updated: 24/09/2026, 17:38:56
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
No summaries found.
- Share price
- $84.95
- Market cap
- $9.00B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- R. Scott Struthers
- Employees
- 594
- IPO date
- 18/07/2018
- Beta
- 0.13017209
- Last dividend
- $0.00
- Day range
- $84.95 – $84.95
- 52-week range
- $32.30 – $85.01
- 1-day performance
- 0.00%
- 1-year performance
- 163.00%
- Current drawdown (1Y)
- -0.07%
- CIK
- 0001658247
- CUSIP
- 22663K107
- ISIN
- US22663K1079
- Created
- 07/12/2025, 03:27:00
- Last update
- 24/09/2026, 17:38:56
Track Crinetics Pharmaceuticals, Inc. with an AI analyst
See which prediction-market events move CRNX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy' Initiative to Empower People Across Endocrine Disease Communities
GlobeNewsWire • STOCK • 02/06/2026, 18:05:00
Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 08/05/2026, 04:11:20
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue Estimates
Zacks Investment Research • STOCK • 07/05/2026, 20:55:19
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
GlobeNewsWire • STOCK • 27/04/2026, 19:13:00
Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More
The Motley Fool • STOCK • 27/03/2026, 20:56:18
Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript
Seeking Alpha • STOCK • 26/02/2026, 23:37:48
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates
Zacks Investment Research • STOCK • 26/02/2026, 20:01:37
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
GlobeNewsWire • STOCK • 05/02/2026, 17:05:00